DXCM 덱스콤 주가 전망 2026: 연속혈당측정기 1등의 성장통, 지금 살 때인가
DXCM 덱스콤 2026년 주가 전망. 매출 $48.2억 TTM +16.2% 성장, EPS 75.5% 급증, PE 30.8배, 52주 저점 $54.1 대비 회복세, GLP-1 약물 확산과 CGM 시장 상관관계 분석, 한국 투자자 세금 포함.
DXCM 덱스콤 미국주식
DXCM Dexcom Stock Outlook 2026: CGM Leader After the Crash — Is the Story Intact?
Dexcom (DXCM) stock analysis 2026: $4.82B TTM revenue up 16.2%, EPS +75.5% to $2.34, P/E 30.8x, GLP-1 drug interaction with CGM adoption, Stelo OTC launch, FreeStyle Libre competition, and analyst consensus Strong Buy with $81.64 target.
DXCM Dexcom CGM
Perspectiva acción DXCM 2026: Dexcom tras el crash del 40% — ¿Sigue siendo la apuesta en monitoreo de glucosa?
Análisis de Dexcom (DXCM) para 2026: ingresos TTM $4.82 mil millones creciendo 16.2%, BPA +75.5% a $2.34, P/E 30.8x, la relación entre GLP-1 y CGM, lanzamiento de Stelo OTC, competencia con FreeStyle Libre, y cómo invertir desde Latinoamérica.
DXCM Dexcom CGM